Efficacy and Safety of Sotatercept Across Ranges of Cardiac Index in Patients with Pulmonary Arterial Hypertension: A Pooled Analysis of PULSAR and STELLAR

BACKGROUND: This analysis compared effects of the activin signaling inhibitor, sotatercept, across pulmonary arterial hypertension (PAH) subgroups stratified by baseline cardiac index (CI). METHODS: Pooled data from PULSAR (N=106; NCT03496207) and STELLAR (N=323; NCT04576988) were analyzed using two different CI thresholds, < and

• Gomberg-Maitland, M.
• Badesch, D. B.
• Gibbs, J. S. R.
• Grünig, E.
• Hoeper, M. M.
• Humbert, M.
• Kope
• McLaughlin, V. V.
• Meyer, G.
• Olsson, K. M.
• Preston, I. R.
• Rosenkranz, S.
• Souza, R.
• Waxman, A. B.
• Perchenet, L.
• Strait, J.
• Xing, A.
• Johnson-Levonas, A. O.
• Cornell, A. G.
• Pena, J. O.
• Ardeschir Ghofrani, H.